WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
复制标题
WT1肽疫苗使顽固性卵巢癌患者稳定一年：病例报告。
作者：
S. Dohi;S. Ohno;Y. Ohno;M. Takakura;S. Kyo;G. Soma;H. Sugiyama;M. Inoue
未标记
我们报告肾母细胞瘤（WT 1）肽免疫治疗的患者与顽固性卵巢癌患者在一个较长的时期。
病例报告
使用WT 1肽的免疫疗法已经进行了妇科癌症的临床试验。我们使用WT 1肽疫苗接种治疗一名53岁的妇女患有卵巢癌腹膜传播。2个月后，她的胸腔积液和心包积液消失，靶病变（盆腔肿块）的最长直径之和减小。CA 125与单核吞噬细胞/淋巴细胞比值呈弱正相关（斯皮尔曼氏系数=0.275，p=0.015）。皮内给予WT 1肽疫苗接种的情况下，顽固性卵巢癌稳定的疾病超过一年的过程。然而，WT 1肽的免疫调节机制和肿瘤细胞的免疫逃逸机制仍有待阐明。
UNLABELLED
We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
CASE REPORT
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.